Previous 10 | Next 10 |
2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...
2024-06-14 08:49:30 ET More on Pfizer Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates Will Boost Re...
Patients in MagnetisMM-3 demonstrated a median overall survival (OS) of 24.6 months, with median progression-free survival (PFS) of 17.2 months Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (e...
2024-06-13 18:34:04 ET More on BioNTech, Moderna, etc. BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcar...
2024-06-13 09:00:00 ET U.S. stock index futures on Thursday were mixed . Wall Street's benchmark and tech-heavy gauges were on track to extend their gains from the previous session, but its blue-chip average looked set to add onto losses. Here are some stocks to watch on Thursday: ...
2024-06-13 09:00:00 ET Summary The markets had a strong week, with the S&P 500 gaining 0.97% and the Dow Jones Industrial Average gaining 1.6%. Yields on the 10-year Treasury shot up to 4.9% ahead of the FOMC meeting. The Dividend Harvesting Portfolio traded sideways but c...
2024-06-13 07:00:26 ET More on Pfizer, Roche, etc. Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates ...
2024-06-13 02:30:42 ET Summary A difficult period for Pfizer might be coming to an end, as serious setbacks and tough Y/Y comps are in the rearview mirror. The first quarter performance of the commercial business exceeded Street expectations, and the company maintained its full-ye...
2024-06-12 17:02:28 ET More on Pfizer Pfizer: Surging Cancer Rates Will Boost Revenues Pfizer: Too Early For A Turnaround Pfizer, Flagship to collaborate on obesity drug discovery Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Globa...
Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
2024-07-20 10:00:00 ET On July 11, Pfizer (NYSE: PFE) made an announcement that came as a bit of a surprise to biopharma industry experts and Wall Street analysts alike. It's planning on advancing one of its early-stage weight loss programs into mid-stage trials. In due time, the mo...
2024-07-18 13:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...